Related references
Note: Only part of the references are listed.FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga
Annemieke Aartsma-Rus et al.
NUCLEIC ACID THERAPEUTICS (2017)
Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophies
Burcu Ayoglu et al.
EMBO MOLECULAR MEDICINE (2014)
Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients
Yetrib Hathout et al.
HUMAN MOLECULAR GENETICS (2014)
Clinical characterisation of Becker muscular dystrophy patients predicts favourable outcome in exon-skipping therapy
J. C. van den Bergen et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2014)
Assessing the value of matrix metalloproteinase 9 (MMP9) in improving the appropriateness of referrals for colorectal cancer
S. Damery et al.
BRITISH JOURNAL OF CANCER (2013)
An urgent need for a change in policy revealed by a study on prenatal testing for Duchenne muscular dystrophy
Apollonia T. J. M. Helderman-van den Enden et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2013)
The cooperative international neuromuscular research group Duchenne natural history study: Glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures
Erik K. Henricson et al.
MUSCLE & NERVE (2013)
THE 6-MINUTE WALK TEST AND OTHER CLINICAL ENDPOINTS IN DUCHENNE MUSCULAR DYSTROPHY: RELIABILITY, CONCURRENT VALIDITY, AND MINIMAL CLINICALLY IMPORTANT DIFFERENCES FROM A MULTICENTER STUDY
Craig M. McDonald et al.
MUSCLE & NERVE (2013)
Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches
Rebecca J. Fairclough et al.
NATURE REVIEWS GENETICS (2013)
195th ENMC International Workshop: Newborn screening for Duchenne muscular dystrophy 14-16th December, 2012, Naarden, The Netherlands
Juliet A. Ellis et al.
NEUROMUSCULAR DISORDERS (2013)
194th ENMC international workshop. 3rd ENMC workshop on exon skipping: Towards clinical application of antisense-mediated exon skipping for Duchenne muscular dystrophy 8-10 December 2012, Naarden, The Netherlands
Annemieke Aartsma-Rus et al.
NEUROMUSCULAR DISORDERS (2013)
Matrix Metalloproteinase-9 Inhibition Improves Proliferation and Engraftment of Myogenic Cells in Dystrophic Muscle of mdx Mice
Sajedah M. Hindi et al.
PLOS ONE (2013)
Phase 2a Study of Ataluren-Mediated Dystrophin Production in Patients with Nonsense Mutation Duchenne Muscular Dystrophy
Richard S. Finkel et al.
PLOS ONE (2013)
Splice Modulating Therapies for Human Disease
Pietro Spitali et al.
CELL (2012)
IGF-II and MMP9 as surgical repair indicators of ventricular septal defects
Chen-Yen Tsai et al.
CLINICA CHIMICA ACTA (2011)
Seasonal variation and stability of matrix metalloproteinase-9 activity and tissue inhibitor of matrix metalloproteinase-1 with storage at-80 °C
G. P. Tarr et al.
CLINICAL BIOCHEMISTRY (2011)
Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study
Sebahattin Cirak et al.
LANCET (2011)
Histone Deacetylase Inhibitors in the Treatment of Muscular Dystrophies: Epigenetic Drugs for Genetic Diseases
Silvia Consalvi et al.
MOLECULAR MEDICINE (2011)
Chronic Systemic Therapy With Low-dose Morpholino Oligomers Ameliorates the Pathology and Normalizes Locomotor Behavior in mdx Mice
Alberto Malerba et al.
MOLECULAR THERAPY (2011)
Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD)
V. D. Nadarajah et al.
NEUROMUSCULAR DISORDERS (2011)
Systemic Administration of PRO051 in Duchenne's Muscular Dystrophy
Nathalie M. Goemans et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Relation of Matrix Metalloproteinase-9/Tissue Inhibitor of Metalloproteinase-1 Ratio in Peripheral Circulating CD14+Monocytes to Progression of Coronary Artery Disease
Stefan Brunner et al.
AMERICAN JOURNAL OF CARDIOLOGY (2010)
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management
Katharine Bushby et al.
LANCET NEUROLOGY (2010)
Preclinical PK and PD Studies on 2′-O-Methyl-phosphorothioate RNA Antisense Oligonucleotides in the mdx Mouse Model
Hans Heemskerk et al.
MOLECULAR THERAPY (2010)
ACTIVIN IIB RECEPTOR BLOCKADE ATTENUATES DYSTROPHIC PATHOLOGY IN A MOUSE MODEL OF DUCHENNE MUSCULAR DYSTROPHY
Kevin J. Morine et al.
MUSCLE & NERVE (2010)
Matrix metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal muscle regeneration in muscular dystrophy
Hong Li et al.
HUMAN MOLECULAR GENETICS (2009)
Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy
Yi Lai et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
In vivo comparison of 2′-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping
Hans A. Heemskerk et al.
JOURNAL OF GENE MEDICINE (2009)
Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. (vol 8, pg 918, 2009)
M. Kinali et al.
LANCET NEUROLOGY (2009)
Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study
Maria Kinali et al.
LANCET NEUROLOGY (2009)
Differences in both matrix metalloproteinase 9 concentration and zymographic profile between plasma and serum with clot activators are due to the presence of amorphous silica or silicate salts in blood collection devices
Ferdinando Mannello et al.
ANALYTICAL BIOCHEMISTRY (2008)
Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer
Zheng-Sheng Wu et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
PTC124 targets genetic disorders caused by nonsense mutations
Ellen M. Welch et al.
NATURE (2007)
Comparative analysis of antisense oligonucleotide sequences for targeted skipping of Exon 51 during dystrophin Pre-mRNA splicing in human muscle
V. Arechavala-Gomeza et al.
HUMAN GENE THERAPY (2007)
Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs
Maurilio Sampaolesi et al.
NATURE (2006)
Plasma storage at-80°C does not protect matrix metalloproteinase-9 from degradation
D Rouy et al.
ANALYTICAL BIOCHEMISTRY (2005)
Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients
A Aartsma-Rus et al.
HUMAN MOLECULAR GENETICS (2003)
Functional improvement of dystrophic muscle by myostatin blockade
S Bogdanovich et al.
NATURE (2002)
Circadian variations of the serum creatine kinase level - a masking effect?
C Gutenbrunner
CHRONOBIOLOGY INTERNATIONAL (2000)
Share Paper
